Hours after the ruling, one company — DNATraits, part of Houston-based Gene By Gene, Ltd. — said it would offer BRCA gene testing in the United States for $995 — less than a third of the current price.
Doctors aren't going to run out and start ordering tests where there is basically no data to back it up. It doesn't matters if its DGX, DBATraits, Aubry, or LabCorp it doesn't really matter. One last thing, the method of testing is still the thing that matters and we have no idea how any of these companies actually do the test. SCOTUS basically said that was still protected. I really wouldn't go short this thing just yet.
Well you have 2 different markets for BRCA tetsing. The physician market and the genetic counselor market. Myriad will likely hold onto physician market but will for sure lose the GC market. This company is hated by the genetics community. I can assure you that none of these companies launching BRCA are doing it using cDNA so it doesn't matter. Next-Gen sequencing wasn't around when Myriad filed patents so that method is free and open.
That would depend on the person. I think there are many people who cannot afford 3000 dollars for the test, particularly if their insurance won't pay for it. Also many insurance companies who do pay for the test may consider cheaper alternatives. Either way prices are going to come down. Myriad no longer has the monopoly it once had.